Modeled cost-effectiveness analysis of autologous haemopoietic stem cell transplantation compared with standard dose chemotherapy for relapsed, aggressive non-Hodgkin’s lymphoma  by Prajogo, J. et al.
melting curve analysis to classify positive samples into 2 groups,
antifungal-resistant and antifungal-susceptible. Conclusions: Us-
ing a novel molecular beacon probe, we have developed a pan-
Candida assay that can detect, quantify, and distinguish between
antifungal-resistant and antifungal-susceptible Candida species.
With further clinical validation, we hope that this assay will pro-
vide physicians a rapid means of identifying Candida infection
directly from clinical samples and assist in institution of early
therapy to reduce the hospital stay and high overall costs associated
with management of candidemia.
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DEVELOPMENT OF A REAL-TIME PCR ASSAY TO DIAGNOSE INVASIVE
ASPERGILLOSIS
Reddy, S.1, Grantham, K.1, Nath, R.2, Dalal, J.3, Manna, P.1 1De-
partment of Molecular Diagnostic Research, ViraCor Laboratories, Lee’s
Summit, MO; 2St Joseph Regional Medical Center, Patterson, NJ;
3Children’s Mercy Hospital, Kansas City, MO.
Background: Invasive Aspergillosis causes signiﬁcant morbidity
and mortality in bone marrow transplantation recipients. In the
absence of rapid, sensitive, speciﬁc, and quantitative diagnostic
assays, it is estimated that  90% of undiagnosed and untreated
cases result in death. Here we report a rapid, sensitive, and speciﬁc
real time PCR assay to diagnose Aspergillus infections. Methods:
We set out to develop a real-time PCR method to detect and
quantify 8 medically important Aspergillus species (A. fumigatus, A.
clavatus, A. ﬂavus, A. glaucus, A. nidulans, A. niger, A. terreus, and A.
versicolor) in a single assay. We carefully aligned several Aspergillus
multicopy rRNA genes to search for a target that is both speciﬁc
for Aspergillus and conserved for all 8 species. To evaluate the
diagnostic utility of a potential target, we performed real-time
PCR on blood specimens that were spiked with serially diluted
conidia from each of these 8 species. Additionally, we evaluated the
effects of DNA extraction yield on the assay’s sensitivity. For this
purpose, we evaluated 3 commercially available DNA extraction
kits: EZNA, Qiagen, and MagNA Pure DNA extraction methods.
Results: Through sequence analysis, we designed a primer pair
and TaqMan probe speciﬁc for a region of the 18s rRNA gene that
is conserved for all 8 species. On application, our results demon-
strate that this assay can detect and quantify as few as 100 copies of
all 8 medically signiﬁcant Aspergillus conidia per mL of spiked
blood. In evaluating 3 commercially available DNA extraction kits,
we found that the EZNA kit provided the maximum DNA yield
and increased assay sensitivity. Moreover, we determined that
mechanical disruption of the specimen by glass beads resulted in
higher DNA yield and increased assay sensitivity. Conclusion:
Developing a single molecular diagnostic assay for all medically
important Aspergillus species is major challenge. Currently we are
performing both retrospective and prospective studies to evaluate
its diagnostic utility. Recently, the galactomannan-based assay
showed promise in diagnosis of invasive aspergillosis; however, it
still has high false-positivity and false-negativity. Furthermore, an
optimum OD cutoff value has yet to be established for early
diagnosis. Therefore, real-time PCR assay can provide an alterna-
tive means of diagnosis of invasive aspergillosis.
219
RELATIONSHIP OF BK VIRAL LOAD IN BLOOD AND URINE WITH THE
SEVERITY OF HEMORRHAGIC CYSTITIS (HC) AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION (HSCT)
Janbay, N.1, De Bari, V.1, Manna, P.2, Visweshwar, N.1, David, C.1,
Lange, M.1, Sterrett, J.R.1, Nath, R.1 1Saint Joseph’s Regional Medical
Center, Paterson, NJ; 2ViraCor Laboratories, Lee’s Summit, MO.
Background: Hemorrhagic cystitis is a frequent and potentially
serious complication after HSCT. An association between BK
virus in the blood and/or urine and late-onset hemorrhagic cystitis
has been described in literature. The role of BK virus in the
pathogenesis of HC is currently unknown, but it has been sug-
gested by the strong temporal correlation between the onset of
viruria and HC. The goal of this study was to evaluate the rela-
tionship between BK virus load in blood and urine and the severity
of HC after HSCT. Methods: We retrospectively analyzed the
records of 8 patients who had BK virus associated HC after HSCT
seen at our institution between June 2002 and June 2004. All of the
patients were male, with a median age of 45 years (range, 24–61
years). The severity of HC was graded according to the number of
RBCs in the urine: grade 1 (RBCs 50), grade 2 (RBCs 50–100),
grade 3 (RBCs  100), or grade 4 (macroscopic hematuria with/
without clots). Grade 1 and 2 were subdivided into grades 1a/2a
(without symptoms) and 1b/2b (with symptoms of suprapubic pain
and/or dysuria). BK viral load in blood and urine specimens was
measured by a real-time PCR assay done by ViraCor Laboratories.
The Shapiro-Wilks test was used to determine goodness of ﬁt for
normal distributions. The data were found to be nonnormally
distributed, and so correlations were assessed using Spearman’s
test. Results: There was a signiﬁcant correlation between BK viral
load in the urine and the number of RBCs in the urine (P  .0005,
95% conﬁdence interval [CI]  0.1968–0.62550). There was also
a signiﬁcant correlation between BK viral load in the blood and BK
viral load in the urine (P  .0008, 95% CI  0.1807–0.6153).
Conclusion: This study suggests a strong correlation between BK
viruria and the severity of HC, as well as a strong correlation
between BK viruria and BK viremia. More studies are needed to
determine the implications of these correlations on early diagnosis
and treatment of BK viral infection.
LYMPHOMA/MULTIPLE MYELOMA
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MODELED COST-EFFECTIVENESS ANALYSIS OF AUTOLOGOUS HAEMO-
POIETIC STEM CELL TRANSPLANTATION COMPARED WITH STANDARD
DOSE CHEMOTHERAPY FOR RELAPSED, AGGRESSIVE NON-HODGKIN’S
LYMPHOMA
Prajogo, J.1, Rowlings, P.A.2, Neil, A.1, Duke, J.1, Zhang, H.2,
Stokes, B.3 1CCEB, University of Newcastle, Newcastle, NSW, Austra-
lia; 2HAPS, Newcastle Mater Hospital, Waratah Newcastle, NSW,
Australia; 3Department of Clinical Pharmacology, University of New-
castle, NSW, Australia.
Background: Salvage of patients with relapsed aggressive non-
Hodgkin’s lymphoma (NHL) before the mid-1990s involved stan-
dard dose chemotherapy (SDC). High-dose chemotherapy (HDC)
combines the same initial drugs as SDC for 2–3 cycles, followed by
high- dose regimes (conditioning) with autologous haemopoietic
stem cell transplantation (AHSCT). In 1995, superior survival for
HDC vs SDC was demonstrated in a European randomized trial
(Philip et al. N Engl J Med 1995;333:1540–5), and HDC rapidly
became the treatment of choice. Because HDC involves substitut-
ing conditioning treatment supported by AHSCT for 3–4 cycles of
SDC, the cost of HDC is higher. The aim of the present study was
to calculate the incremental cost-effectiveness ratio (ICER) for
HDC compared with SDC using Australian costs and the Euro-
pean trial data. Methods: 21 patients transplanted from 1995 to
2002 with characteristics similar to those of the European trial
were identiﬁed from the HDC database of the Newcastle Mater
Hospital (NMH). All drug, transfusion, inpatient and outpatient
attendance, and similar relevant data from start of salvage treat-
ment up to 100 days after conditioning and AHSCT were obtained
and costed. SDC costs required modeling, because all suitable
patients are scheduled to receive HDC if possible, and thus no
concurrent SDC arms exist. SDC cost for 6 cycles of combination
chemotherapy was modeled from data available from the cycles
received before HDC. The European trial survival data were used
because NMH patients were treated only with HDC, patient
numbers were small, and follow-up was short. A lifetime estimate
of patient-years gained by HDC versus SDC was calculated from
the area under survival curves (AUCs) of HDC and SDC from zero
to inﬁnity. Costs and beneﬁts were discounted in advance at 5%
per annum. The ICER was calculated according to the following
formula: incremental cost 
 incremental beneﬁt  (costsHDC 
costsSDC) 
 (AUCHDC  AUCSDC). Results: Costs for HDC and
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SDC were $AU37,491 and $AU33,360, respectively, with an in-
cremental cost of $AU4,131. The AUC0-inﬁnity was 6.5 and 3.5
patient life-years, respectively, leading to an incremental beneﬁt of
3.0 life-years gained. This gives an ICER of $AU1,377 per dis-
counted life-year gained. Compared with published studies of IC-
ERs for HDC versus SDC in multiple myeloma and metastatic
breast cancer, these results support HDC as a cost-effective treat-
ment in relapsed aggressive NHL.
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PHASE II TRIAL OF GM-CSF AS MAINTENANCE THERAPY POST–AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
MULTIPLE MYELOMA
Mandanas, R.A., Beveridge, R., Rifkin, R.M., Greenspan, A.R.,
Orloff, G.J., Klein, L.M., Rauch, M.A., Boehm, K.A., Zhan, F.,
Asmar, L. US Oncology Research, Inc., Houston, TX.
Background: It has been hypothesized that GM-CSF may stim-
ulate monocytes and dendritic cells, resulting in an increased im-
mune-mediated recognition and cytotoxic effect against myeloma.
Methods: Forty study subjects, who did not show progression
within the ﬁrst 120 days following their autotransplantations, were
enrolled at 9 sites throughout the US Oncology transplantation
network. The median age was 59.2 years (range, 42.4–78.7 years),
67.5% were male, 32.5% were white, and the PS scores (0/1) were
62.5% and 37.5%, respectively. Participants were instructed on the
proper technique for giving themselves subcutaneous (SC) injec-
tions at their ﬁrst dose visit. Subsequently, subjects self-adminis-
tered 250 g GM-CSF (Leukine, Berlex Laboratories, Seattle,
WA) SC daily for days 1–14 of each 28-day cycle, for a total of 1
year. Nonhematologic toxicities were managed symptomatically if
they were grade 2 (excluding nausea and alopecia); for toxici-
ties  grade 3, the treatment was withheld until the event recov-
ered to  grade 1. For WBC count  20,000/mL or platelet
count  500,000/mL, doses of GM-CSF were reduced by 50% (to
125 g). Results: There were 40 eligible participants. At 1 year
from transplantation, 12 subjects relapsed or died, and the product-
limit estimated progression-free survival rate (PFS) was 65.1% (vs
60% in unpublished data). The 2-year PFS was 50.6% (vs 40% in
unpublished data). The median PFS was 16.3 months (range,
5–25.3 months), and at 2 years, the estimated survival was 84%.
Toxicity was limited. Grade 3 or 4 treatment-related events in-
cluded dyspnea and bone pain (5% each) and myalgia and chest
pain (2.5% each). There were 4 deaths; none were treatment-
related. Conclusions: Administration of GM-CSF posttransplan-
tation for myeloma is feasible and may delay progression of the
disease.
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ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) USING REDUCED
INTENSITY CONDITIONING (RIC) IN THE PATIENTS WITH RECURRENT
AND REFRACTORY MALIGNANT LYMPHOPROLIFERATIVE DISORDERS
Raida, L.1, Faber, E.1, Papajik, T.1, Indrak, K.1, Zapletalova, J.2,
Vitek, A.3, Koza, V.4 1Hemato-oncology Department, University Hos-
pital, Olomouc, Czech Republic; 2Centre of Biomedical Information,
Medical School of Palacky University, Olomouc, Czech Republic; 3Insti-
tute of Hematology and Blood Transfusion, Prague, Czech Republic;
4Hemato-oncology Department, University Hospital, Pilsen, Czech Re-
public.
Background: An evidence of graft versus tumor (GvT) effect
revealed a new therapeutic opportunity for conventionally incur-
able patients suffering from lymphoid malignancies. RIC allows us
to achieve the engraftment of donor immunocompetent cells and
to avoid unnecessary toxicity in usually heavily pretreated patients.
We present a cohort of patients allografted after RIC because of
recurrent/refractory malignant lymphoproliferation. Methods:
Nineteen patients (median age, 50 years; range, 33–68 years) with
recurrent/refractory malignant lymphoproliferations (5 cases of
B-CLL [26%], 12 cases of B-NHL [63%], 2 cases of T-NHL
[11%]) were allografted after ﬂudarabine-based RIC. Fifteen pa-
tients (79%) received SCT from sibling donors; 4 (21%), from
unrelated donors. Cyclosporin-A (CSP) was administered as sin-
gle-agent GvHD prophylaxis in 8 (42%) patients. A combination
with methotrexate (MTX) and mycophenolate mofetil (MMF) was
used in 6 (32%) and 5 (26%) patients, respectively. The immuno-
suppression was gradually tapered and stopped between days 30
and 180 based on the therapeutic response, chimerism, and
GvHD development. The median follow-up is 12 months (range,
1–33 months). Results: Seventeen (90%) recipients achieved com-
plete remission (CR) of disease. After SCT, disease relapse and
progression were observed in 4 (21%) and 2 (11%) patients, re-
spectively. Thirteen (68%) patients developed acute, chronic, or
both forms of GvHD. Nine (48%) recipients died. The causes of
death were disease progression in 3 patients (16%) and transplan-
tation-related complications in 6 patients (32%). Estimated 2-year
event-free survival (EFS) was 30%, and estimated overall survival
(OS) was 47%. Conclusions: Our results conﬁrm the evidence of
GvT reaction and effective tumor control in otherwise incurable
patients treated with allografting after RIC. The major problem
remains GvHD and related complications responsible for signiﬁ-
cant morbidity and mortality.
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SALVAGE THERAPY WITH CDME SCHEDULE FOLLOWED BY PBSC
TRANSPLANTATION IN 20 LYMPHOMA PATIENTS: AN INTENTION-TO-
MOBILIZE AND TRANSPLANTATION ANALYSIS
Won, J.-H., Kim, H.-J., Lee, N.-S., Lee, S.-H., Bae, S.-B.,
Kim, C.-K., Lee, K.-T., Park, S.-K., Hong, D.-S., Park, H.-S. Division
of Hematology-Oncology and Institute for Clinical Molecular Biology
Research, Soon Chun Hyang University College of Medicine, Seoul,
Korea.
The combination of mitoxantrone, etoposide, cisplatin, and
dexamethasone (CDME regimen) is an effective salvage regimen
for lymphoproliferative disease. Our study analyzed this combina-
tion in mobilization of peripheral blood stem cells in patients with
relapsed, refractory, or high-risk lymphoma. The study included
20 patients with non-Hodgkin’s lymphoma (NHL) (17 males and
3 females). The median age was 53 years (range, 18–66 years).
According to the working formulation, there were 13 patients with
intermediate grade, 6 with high grade, and 1 with low grade.
Age-adjusted IPI analysis showed 8 patients with 1 risk factor, 10
with 2 risk factors, and 2 with 3 risk factors. After 2 courses of
CDME, the overall and complete response (CR) rates were 65%
and 30%, respectively. Mobilization was successful in all patients.
The median MNC yield was 7.85  108/kg (range, 3.49–20.12),
and CD34 cell yield was 11  106/kg (range, 2.08–38.7). No
factors affect the mobilization outcome after CDME schedule. All
patients received high-dose chemotherapy and autologous periph-
eral blood stem cell transplantation (PBSCT), and 1 toxicity-
related death occurred. In autografts carried out using CDME-
mobilized PBSC, the median time to neutrophils  500/mm3 was
10 days (range, 1–44 days) and that to platelets  20,000/mm3 was
11 days (range, 2–47 days). The overall response rate was 78.9%
(CR 68.4% and PR 10.5%), and median PFS and OS were 9 and
16 months, respectively, after PBSCT. In multivariate analysis,
ECOG performance status, age-adjusted IPI, and disease status
before transplantation were signiﬁcantly associated with PFS and
OS. Our results demonstrate that the CDME regimen is effective
in refractory or relapsed NHL, resulting in successful stem cell
mobilization.
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GM-CSF AND INTERFERON- MAINTENANCE THERAPY FOR MULTIPLE
MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTA-
TION (ASCT): AN INTERIM REPORT
Gowda, S., Cogle, C.R., Khan, S.A., Moreb, J.S. University of Florida,
College of Medicine, Gainesville, FL.
Maintenance therapy with IFN-	 has been shown to delay mul-
tiple myeloma (MM) relapse with variable effect on overall sur-
vival. In our experience, 30% of patients are unable to effectively
take IFN-	 after ASCT because of IFN-	–induced cytopenias. We
hypothesize that the inclusion of GM-CSF will prevent the my-
elosuppresion by IFN-	 and may further improve the clinical
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